TMCI

$1.24-0.07 (-5.34%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.24
Potential Upside
5%
Whystock Fair Value$1.30
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-56.31%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.13

Recent News

Simply Wall St.
Mar 20, 2026

How The Story Is Shifting For Treace Medical Concepts (TMCI) After Analyst Target Resets

Analysts have shifted their price targets on Treace Medical Concepts into a lower single digit range, with modelled fair value moving from US$4.20 to US$3.85 as part of a refreshed view on the stock. This reset lines up with a split narrative, where bullish voices highlight supportive Q4 data and perceived limited downside, while more cautious analysts point to execution risks and mixed product trends. As you read on, you will see how these differing views are shaping the evolving story...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 28, 2026

Treace Medical Concepts, Inc. Q4 2025 Earnings Call Summary

Moby summary of Treace Medical Concepts, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Feb 27, 2026

Treace Medical Concepts Inc (TMCI) Q4 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a revenue dip, Treace Medical Concepts Inc (TMCI) focuses on product innovation and market expansion to drive future growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 27, 2026

Treace Medical Concepts Q4 Earnings Call Highlights

Treace Medical Concepts (NASDAQ:TMCI) management told investors it is entering what it called a “transformational phase,” expanding beyond its historical Lapiplasty focus to become a broader “comprehensive bunion solutions company.” On the company’s fourth quarter and full-year 2025 earnings call, e

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Feb 27, 2026

Treace Medical Concepts: Q4 Earnings Snapshot

The Ponte Vedra, Florida-based company said it had a loss of 15 cents per share. Losses, adjusted to extinguish debt, were 12 cents per share. The results beat Wall Street expectations.

BEARISH
Negative press. News cycle fixated on risk factors or misses.